Cholesterol, statins and the numbers behind them

Few medical decisions are as contested in public and as settled in the evidence as whether to take a statin.

What is measured

A lipid panel typically reports total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides, with non-HDL cholesterol increasingly used as the more informative figure.

LDL is causally implicated in atherosclerosis, supported by trial, genetic and epidemiological evidence that is unusually consistent.

HDL is inversely associated with risk, and drugs that raise it have not reduced events, which suggests it is a marker rather than a target.

Triglycerides matter, particularly at high levels where pancreatitis becomes a risk.

Lipoprotein(a) is genetically determined, is measured once in a lifetime in some guidance, and identifies a group at elevated risk.

Why the number alone does not decide

The important conceptual point.

Treatment decisions are based on estimated overall cardiovascular risk over ten years or a lifetime, calculated from age, sex, smoking, blood pressure, diabetes, cholesterol, family history and other factors.

Which means two people with identical cholesterol can reasonably receive different advice.

Thresholds for offering treatment vary between countries, commonly around a ten per cent ten-year risk, with lower thresholds for people who already have cardiovascular disease, diabetes, chronic kidney disease or familial hypercholesterolaemia.

Anyone who has already had a cardiovascular event is in a different category entirely, where treatment is clearly beneficial.

What statins do

The evidence base is among the largest for any drug class.

Meta-analyses of randomised trials involving very large numbers of participants show that lowering LDL reduces major vascular events, with the benefit proportional to the reduction achieved and largely independent of the starting level.

Benefit accumulates over years, which is why they are a long-term rather than a short-term intervention.

The absolute benefit depends on baseline risk, which is why the same relative reduction means a great deal to a high-risk person and little to a low-risk one.

Side effects, stated fairly

Where public perception and trial data diverge.

Muscle symptoms are the most commonly reported reason for stopping.

Blinded trials and n-of-1 studies, in which patients alternate between statin and placebo without knowing which, have consistently found that most muscle symptoms occur equally on placebo — a nocebo effect.

Genuine statin-associated muscle symptoms exist and are less common than reported; severe myopathy and rhabdomyolysis are rare.

A small increase in new diabetes diagnoses is established, generally in people already close to the threshold, and is outweighed by cardiovascular benefit in those for whom treatment is indicated.

Liver enzyme rises are usually minor.

Practical response to symptoms: rechallenge, a different statin, a lower dose or alternate-day dosing frequently resolves it, and stopping entirely is rarely necessary.

The alternatives

For those who genuinely cannot tolerate statins or need further reduction.

Ezetimibe, which is now generic and inexpensive and has additive benefit.

Bempedoic acid.

PCSK9 inhibitors and inclisiran, which are highly effective and expensive, and are reserved for high-risk patients under specific criteria.

And in familial hypercholesterolaemia, specialist management, since this is a genetic condition affecting a meaningful proportion of the population that is substantially underdiagnosed and where early treatment transforms outcomes.

Diet and lifestyle

Which matter and are frequently oversold as a substitute.

Replacing saturated fat with unsaturated fat lowers LDL, with the strongest evidence for polyunsaturated replacement.

Soluble fibre, plant stanols and sterols produce modest reductions.

Weight loss, physical activity and stopping smoking all improve the overall risk picture.

Alcohol reduction lowers triglycerides.

Realistically, dietary change alone produces a smaller LDL reduction than a moderate statin dose, which is why it is offered alongside rather than instead of medication for higher-risk people.

Dietary cholesterol — eggs and similar — has a much smaller effect on blood cholesterol than saturated fat, which is where advice has shifted.

What it costs

Unusually favourable arithmetic.

Generic statins are among the cheapest medicines available, at a few units of currency per month.

Ezetimibe is now similarly inexpensive.

Against which the cost of a myocardial infarction or stroke — acute care, rehabilitation, medication afterwards, lost earnings and possible long-term care — is in a different order of magnitude entirely.

Which is why statins are among the most cost-effective interventions in preventive medicine and are prioritised accordingly in health systems.

Making the decision

The questions worth asking.

What is my ten-year risk, calculated properly?

What difference would treatment make to that number in absolute terms?

What are my modifiable risk factors, and what would addressing them do?

What are the alternatives if I do not tolerate it?

And what happens if I do nothing — which is a legitimate option that should be discussed rather than dismissed.

General information only, not medical advice. Consult a qualified clinician about cardiovascular risk and treatment, and do not stop prescribed medication without advice.